Effect of dexamethasone supplementation on chondrogenesis of equine mesenchymal stem cells.

This research paper investigates whether the combination of using fibroblast growth factor-2 (FGF-2) and dexamethasone can improve the chondrogenic differentiation – the process by which cells become cartilage – of equine mesenchymal stem cells (MSCs). The results show that the combination does lead to an increase in certain characteristics associated with cartilage, as well as a maintained DNA content over time. The stimulation of a type of enzyme activity related to bone formation was also observed, which could be significant for MSC-based techniques in cartilage repair.

Research Methods and Process

• The researchers began with MSCs sourced from five young horses. The stem cells were proliferated through a method called first-passage equine monolayer, a technique that allows for rapid cell expansion.
• To stimulate growth, the researchers added FGF-2, a protein involved in cell growth and regeneration. The cells were also supplemented with dexamethasone, a steroid known to stimulate chondrogenic differentiation.
• These proliferated stem cells were then placed into pellet cultures and maintained with a medium designed to favour the formation of cartilage.
• The research team collected the formed pellets after 1, 7, and 14 days to analyse for markers that indicated successful chondrogenesis such as collagen type II protein, total glycosaminoglycan content, total DNA content, alkaline phosphatase (ALP) activity and certain mRNA types.

Results and Analysis

• The results revealed a promising effect of FGF-2 and dexamethasone on the chondrogenic differentiation of MSCs. The pellets treated with these supplements showed higher levels of collagen type II, glycosaminoglycan, and aggrecan mRNA expression, all of which are crucial components of cartilage tissue.
• Moreover, the DNA content of the control MSCs (those not treated with FGF-2 and dexamethasone) decreased over time, a trend not observed in the treated MSCs. This suggests that the supplements protected against DNA loss.
• A significant increase was noted in ALP activity and mRNA levels in the MSCs treated with both FGF-2 and dexamethasone, indicating possible progression from cartilage toward bone formation.

Conclusions

• The combination of FGF-2 and dexamethasone appears to enhance the chondrogenic differentiation of MSCs. This development is mainly attributed to an increase in the number of MSCs due to the protective effect against DNA loss.
• The stimulated ALP activity infers that this differentiation process also gradually progresses the cartilage toward bone formation. Recognising this may be significant for MSC-based therapies aimed at repairing damaged cartilage, particularly in the field of equine medicine.